InsiderTrades.com logo
Michael F. Huang net worth and biography
  • LinkedIn
  • Phone
  • Email
  • Website

Michael Huang Biography and Net Worth

VP of Soleno Therapeutics

Dr. Huang joined the Company as Senior Vice President, Clinical Development in November 2023. He has a history of successfully advancing small molecules, biologics, and oligonucleotide therapies through all phases of clinical development. He was involved in marketing authorizations for several therapeutics including Potiga®, Zevalin®, Uceris®, Ruconest®, and Austedo®. Prior to joining Soleno, Dr. Huang held CMO roles at AmMax Bio, Inc. and Spruce Biosciences, where led their respective rare disease clinical development programs through proof-of-concept and successful rounds of financing. Earlier in his career, Dr. Huang held leadership roles at Regulus Therapeutics, Auspex Pharmaceuticals (until its acquisition by Teva), and Santarus, Inc. (until its acquisition by Salix). Dr. Huang received his bachelor’s degree in molecular and cell biology from the University of California at Berkeley, his medical degree from the Chicago Medical School at Rosalind Franklin University, and his post-graduate internship and residency training from the University of California at Irvine / Long Beach Memorial Medical Center. Dr. Huang is the author or co-author of numerous peer-reviewed journal articles, abstracts, and scientific publications.

What is Michael F. Huang's net worth?

The estimated net worth of Michael F. Huang is at least $2.53 million as of March 27th, 2025. Dr. Huang owns 36,817 shares of Soleno Therapeutics stock worth more than $2,534,298 as of April 17th. This net worth approximation does not reflect any other assets that Dr. Huang may own. Learn More about Michael F. Huang's net worth.

How old is Michael F. Huang?

Dr. Huang is currently 50 years old. There are 5 older executives and no younger executives at Soleno Therapeutics. The oldest executive at Soleno Therapeutics is Mr. James H. MacKaness, Chief Financial Officer, who is 60 years old. Learn More on Michael F. Huang's age.

How do I contact Michael F. Huang?

The corporate mailing address for Dr. Huang and other Soleno Therapeutics executives is 203 REDWOOD SHORES PARKWAY SUITE 500, REDWOOD CITY CA, 94065. Soleno Therapeutics can also be reached via phone at (650) 213-8444 and via email at ir@soleno.life. Learn More on Michael F. Huang's contact information.

Has Michael F. Huang been buying or selling shares of Soleno Therapeutics?

Michael F. Huang has not been actively trading shares of Soleno Therapeutics during the last quarter. Most recently, Michael F. Huang sold 14,583 shares of the business's stock in a transaction on Thursday, March 27th. The shares were sold at an average price of $69.51, for a transaction totalling $1,013,664.33. Following the completion of the sale, the vice president now directly owns 36,817 shares of the company's stock, valued at $2,559,149.67. Learn More on Michael F. Huang's trading history.

Who are Soleno Therapeutics' active insiders?

Soleno Therapeutics' insider roster includes Anish Bhatnagar (CEO), Patricia Hirano (Insider), Michael Huang (VP), James Mackaness (CFO), Matthew Pauls (Director), Jack Schuler (Major Shareholder), and Kristen Yen (Senior Vice President, Clinical Operations). Learn More on Soleno Therapeutics' active insiders.

Are insiders buying or selling shares of Soleno Therapeutics?

In the last twelve months, insiders at the sold shares 24 times. They sold a total of 2,510,089 shares worth more than $139,065,642.37. The most recent insider tranaction occured on April, 1st when insider Patricia C Hirano sold 3,782 shares worth more than $265,156.02. Insiders at Soleno Therapeutics own 12.3% of the company. Learn More about insider trades at Soleno Therapeutics.

Information on this page was last updated on 4/1/2025.

Michael F. Huang Insider Trading History at Soleno Therapeutics

See Full Table

Michael F. Huang Buying and Selling Activity at Soleno Therapeutics

This chart shows Michael F Huang's buying and selling at Soleno Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table
2022202320242025$0bought$0soldQ2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1Q2-$1M-$500k$0$500k$1MTotal Insider BuyingTotal Insider Selling

Soleno Therapeutics Company Overview

Soleno Therapeutics logo
Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Extended-Release tablets, a once-daily oral tablet, which is in Phase III clinical trials for the treatment of Prader-Willi Syndrome. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeutics, Inc. was incorporated in 1999 and is based in Redwood City, California.
Read More

Today's Range

Now: $69.98
Low: $68.34
High: $70.51

50 Day Range

MA: $54.36
Low: $43.68
High: $73.67

2 Week Range

Now: $69.98
Low: $36.61
High: $74.00

Volume

1,236,195 shs

Average Volume

719,103 shs

Market Capitalization

$3.21 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A